ArticlePloS one2026
Psychometric properties of the Persian version of the chemotherapy side effects fear scale among Iranian patients with cancer.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fear of chemotherapy-induced side effects is a major concern among patients with cancer and may affect psychological well-being and treatment adherence. This methodological study aimed to translate, culturally adapt, and evaluate the psychometric properties of the Persian version of the Chemotherapy Side Effects Fear Scale (CheSeFS). The study was conducted from January to April 2024 at the Cancer Institute of Imam Khomeini Hospital Complex in Tehran, Iran, and included 600 patients undergoing chemotherapy. The CheSeFS underwent forward-backward translation and cross-cultural adaptation. Face and content validity, structural validity, convergent and discriminant validity, internal consistency, test-retest reliability, measurement error, a distribution-based MIC estimate, and factors associated with CheSeFS scores were evaluated. All statistical analyses were performed using Jamovi version 2.7.1 and included descriptive statistics, item analysis, exploratory factor analysis, confirmatory factor analysis, reliability and measurement error analyses, convergent and discriminant validity assessment, distribution-based MIC estimation, and regression analysis. Patient and expert evaluations supported face and content validity. Exploratory factor analysis identified a two-factor structure, including Physiological fear and Subjective or Psychological fear, explaining 54.4% of the total variance. Three items were removed during factor analysis, resulting in a final 11-item scale. Confirmatory factor analysis supported model fit, with χ²(df = 43) = 84.2, RMSEA = 0.06, CFI = 0.99, TLI = 0.99, and SRMR = 0.04. Internal consistency was satisfactory, with Cronbach's alpha = 0.89 for the total scale. Measurement error analysis showed an SEM of 1.64 and an MDC95 of 4.56, and the distribution-based MIC estimate was 1.01 points. The Persian 11-item CheSeFS demonstrated satisfactory validity and reliability for assessing chemotherapy-related fear among Iranian patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.